S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

Alimera Sciences News Headlines (NASDAQ:ALIM)

$6.15
-0.11 (-1.76 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$5.91
Now: $6.15
$6.50
50-Day Range
$6.15
MA: $6.90
$7.76
52-Week Range
$2.96
Now: $6.15
$18.15
Volume16,500 shs
Average Volume39,903 shs
Market Capitalization$30.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15

Headlines

Alimera Sciences (NASDAQ ALIM) News Headlines

Source:
DateHeadline
Alimera Sciences Inc.Alimera Sciences Inc.
www.barrons.com - February 16 at 10:01 PM
Alimera Sciences, Inc. Common Stock (ALIM) Institutional Holdings | NasdaqAlimera Sciences, Inc. Common Stock (ALIM) Institutional Holdings | Nasdaq
www.nasdaq.com - February 14 at 5:32 PM
Alimera Sciences Inc (NASDAQ:ALIM) Short Interest UpdateAlimera Sciences Inc (NASDAQ:ALIM) Short Interest Update
www.americanbankingnews.com - February 11 at 5:58 PM
2020-2026 Diabetic Retinopathy Treatment Market | Emerging Technology, Development, Industry Analysis and Forecasts2020-2026 Diabetic Retinopathy Treatment Market | Emerging Technology, Development, Industry Analysis and Forecasts
www.marketwatch.com - February 11 at 8:11 AM
Alimera Sciences Inc (NASDAQ:ALIM) Expected to Post Quarterly Sales of $14.50 MillionAlimera Sciences Inc (NASDAQ:ALIM) Expected to Post Quarterly Sales of $14.50 Million
www.americanbankingnews.com - February 3 at 1:16 AM
Zacks: Analysts Expect Alimera Sciences Inc (NASDAQ:ALIM) Will Announce Earnings of -$0.37 Per ShareZacks: Analysts Expect Alimera Sciences Inc (NASDAQ:ALIM) Will Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - February 1 at 11:56 PM
Diabetic Retinopathy Treatment Market Emerging Technology, Development and Forecasts to 2026Diabetic Retinopathy Treatment Market Emerging Technology, Development and Forecasts to 2026
www.marketwatch.com - January 30 at 6:14 AM
Insider Buying: The Alimera Sciences, Inc. (NASDAQ:ALIM) Just Bought US$562k Worth Of SharesInsider Buying: The Alimera Sciences, Inc. (NASDAQ:ALIM) Just Bought US$562k Worth Of Shares
finance.yahoo.com - January 29 at 12:20 PM
Insider Buying: The Alimera Sciences, Inc. (NASDAQ:ALIM)  Just Bought US$562k Worth Of SharesInsider Buying: The Alimera Sciences, Inc. (NASDAQ:ALIM) Just Bought US$562k Worth Of Shares
finance.yahoo.com - January 29 at 7:19 AM
Alimera Sciences, Inc 13D/A filingAlimera Sciences, Inc 13D/A filing
finance.yahoo.com - January 27 at 8:43 AM
Alimera Sciences Inc (NASDAQ:ALIM) Sees Significant Drop in Short InterestAlimera Sciences Inc (NASDAQ:ALIM) Sees Significant Drop in Short Interest
www.americanbankingnews.com - January 27 at 2:39 AM
Diabetic Retinopathy Treatment Market 2020 Global Trend, Segmentation and Opportunities Forecast To 2026Diabetic Retinopathy Treatment Market 2020 Global Trend, Segmentation and Opportunities Forecast To 2026
www.marketwatch.com - January 22 at 7:17 AM
Diabetic Retinopathy Treatment Market to Grow with Mounting Prevalence of Diabetes Worldwide: Fortune Business Insights™Diabetic Retinopathy Treatment Market to Grow with Mounting Prevalence of Diabetes Worldwide: Fortune Business Insights™
www.marketwatch.com - January 15 at 11:57 PM
Alimera Sciences Refinances Its Debt Facility With Solar CapitalAlimera Sciences Refinances Its Debt Facility With Solar Capital
finance.yahoo.com - January 6 at 4:42 PM
Did Hedge Funds Drop The Ball On Alimera Sciences Inc (ALIM) ?Did Hedge Funds Drop The Ball On Alimera Sciences Inc (ALIM) ?
finance.yahoo.com - December 17 at 8:13 PM
Almira Sciences, Inc 13D filingAlmira Sciences, Inc 13D filing
finance.yahoo.com - December 11 at 2:25 PM
Age-Related Macular Degeneration Market to asserts CMI with Major Vendors Size, Shares Estimation and Forecasts up to 2026Age-Related Macular Degeneration Market to asserts CMI with Major Vendors Size, Shares Estimation and Forecasts up to 2026
www.marketwatch.com - December 10 at 12:45 PM
Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019
finance.yahoo.com - December 4 at 9:24 AM
Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior UveitisAlimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis
finance.yahoo.com - December 3 at 1:15 PM
Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare ConferenceAlimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 26 at 4:24 PM
Edited Transcript of ALIM earnings conference call or presentation 30-Oct-19 1:00pm GMTEdited Transcript of ALIM earnings conference call or presentation 30-Oct-19 1:00pm GMT
finance.yahoo.com - November 20 at 8:28 AM
Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock SplitAlimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split
finance.yahoo.com - November 14 at 3:21 PM
Alimera Sciences Terminates Equity Purchase AgreementAlimera Sciences Terminates Equity Purchase Agreement
finance.yahoo.com - November 13 at 8:30 AM
Alimera Sciences announces reverse stock splitAlimera Sciences announces reverse stock split
seekingalpha.com - November 8 at 7:49 AM
Alimera Sciences Announces Board’s Approval of Reverse Stock Split RatioAlimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio
finance.yahoo.com - November 7 at 7:17 PM
One Thing To Remember About The Alimera Sciences, Inc. (NASDAQ:ALIM) Share PriceOne Thing To Remember About The Alimera Sciences, Inc. (NASDAQ:ALIM) Share Price
finance.yahoo.com - November 5 at 9:21 AM
Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New YorkAlimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York
finance.yahoo.com - November 5 at 9:21 AM
Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2019 Results - Earnings Call TranscriptAlimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2019 Results - Earnings Call Transcript
seekingalpha.com - October 30 at 5:40 PM
Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate UpdateAlimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - October 29 at 7:28 PM
Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park CapitalAlimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital
finance.yahoo.com - October 25 at 1:00 PM
Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate UpdateAlimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update
finance.yahoo.com - October 23 at 1:15 PM
Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior UveitisAlimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis
finance.yahoo.com - October 3 at 8:42 AM
Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019
finance.yahoo.com - October 2 at 5:16 PM
Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual MeetingAlimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting
finance.yahoo.com - October 1 at 8:27 AM
Alimera expands Iluvien distribution deal with Horus; shares ahead 10%Alimera expands Iluvien distribution deal with Horus; shares ahead 10%
seekingalpha.com - September 12 at 11:18 AM
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux CountriesAlimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries
finance.yahoo.com - September 12 at 11:18 AM
BRIEF-Alimera Sciences Board Of Directors Approves Reverse Stock Split And 10B5-1 Stock Purchase Plan For U.S. Executive ManagementBRIEF-Alimera Sciences Board Of Directors Approves Reverse Stock Split And 10B5-1 Stock Purchase Plan For U.S. Executive Management
www.msn.com - September 6 at 7:49 AM
Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive ManagementAlimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management
www.nasdaq.com - September 6 at 7:49 AM
Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis IndicationAlimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication
finance.yahoo.com - September 3 at 11:29 AM
Retinal Drugs and Biologics Market Growth Predictions, Leading Players-ALLERGAN, AbbVie and Alimera SciencesRetinal Drugs and Biologics Market Growth Predictions, Leading Players-ALLERGAN, AbbVie and Alimera Sciences
www.marketwatch.com - August 29 at 8:29 AM
How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?
finance.yahoo.com - August 6 at 10:34 AM
Alimeras ILUVIEN now approved in Australia for DMEAlimera's ILUVIEN now approved in Australia for DME
seekingalpha.com - August 5 at 10:22 AM
Advanced Ophthalmology Technologies Market Forecast to 2029 | Profiling Global Players- Novartis, Abbott Medical Optics and Alimera SciencesAdvanced Ophthalmology Technologies Market Forecast to 2029 | Profiling Global Players- Novartis, Abbott Medical Optics and Alimera Sciences
www.marketwatch.com - August 5 at 10:22 AM
Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular EdemaAlimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema
finance.yahoo.com - August 5 at 10:22 AM
Edited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMTEdited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMT
finance.yahoo.com - July 31 at 10:01 PM
Alimera Sciences EPS misses by $0.03, misses on revenueAlimera Sciences EPS misses by $0.03, misses on revenue
seekingalpha.com - July 30 at 11:09 AM
Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate UpdateAlimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - July 29 at 10:19 PM
Eye Disorders Treatments Market Forecast to 2029 | Profiling Global Players - Novartis, Abbott Medical Optics and Alimera SciencesEye Disorders Treatments Market Forecast to 2029 | Profiling Global Players - Novartis, Abbott Medical Optics and Alimera Sciences
www.marketwatch.com - July 29 at 9:05 AM
Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual MeetingAlimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting
finance.yahoo.com - July 23 at 12:15 PM
Alimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate UpdateAlimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate Update
finance.yahoo.com - July 22 at 10:38 AM
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel